{
    "clinical_study": {
        "@rank": "35334", 
        "acronym": "CVAY736X2201", 
        "arm_group": [
            {
                "arm_group_label": "VAY736 dose 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "VAY736 Dose 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to evaluate the safety, tolerability, pharmacokinetics and\n      therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS\n      patients"
        }, 
        "brief_title": "PD of VAY736 in Patients With Primary Sj\u00f6gren's Syndrome", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Sj\u00f6gren's Syndrome", 
        "condition_browse": {
            "mesh_term": "Sjogren's Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "INCLUSION CRITERIA:\n\n          -  Fulfilled revised European US consensus criteria for pSS\n\n          -  ESSDAI value \u2265 6\n\n          -  Elevated serum titers at screening of ANA (\u2265 1:160)\n\n          -  Seropositive at screening for anti-SSA and/or anti-SSB antibodies\n\n          -  Stimulated whole salivary flow rate at screening of > 0 mL/min\n\n        EXCLUSION CRITERIA:\n\n        - Prior or previous use of (specific dosages and intervals prior to study start may\n        apply): B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig\n        (abatacept), anti-TNF-\u03b1 mAb, cyclophosphamide, azathioprine and medications known to cause\n        dry mouth.\n\n        Hydroxychloroquine or methotrexate in a consistent dose for \u2265 3 months prior to\n        randomization is allowed\n\n          -  Active or recent history of clinically significant infection\n\n          -  Vaccination within 2 month prior to study\n\n          -  History of primary or secondary immunodeficiency\n\n          -  Other protocol-defined inclusion/exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149420", 
            "org_study_id": "CVAY736X2201", 
            "secondary_id": "2013-000250-22"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VAY736 dose 1", 
                    "VAY736 Dose 2"
                ], 
                "intervention_name": "VAY736", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "primary Sj\u00f6gren's syndrome, pharmacodynamics", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Strasbourg", 
                        "country": "France", 
                        "zip": "67000"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "10117"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "state": "the Netherlands", 
                        "zip": "3508 GA"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1007 MB"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Germany", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sj\u00f6gren's Syndrome", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "+41613241111"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The effect of VAY736 on clinical disease activity will be measured by the change in ESSDAI (EULAR Sj\u00f6gren's syndrome disease activity index) between baseline and week 12. The ESSDAI is a questionnaire containing 12 organ-specific domains.", 
            "measure": "Change in EULAR Sj\u00f6gren's syndrome disease activity index (ESSDAI)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The ESSPRI is a patient self-reported outcome measure (questionnaires) to assess patient's disease status (e.g. pain, emotional/social/physical functioning, mental health, fatigue).", 
                "measure": "Change in EULAR Sj\u00f6gren's Syndrome Patient Response Index (ESSPRI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "description": "The SF-36 is a patient self-reported outcome measure (questionnaires) to assess patient's disease status and burden, e.g. pain, emotional/social/physical functioning, mental health.", 
                "measure": "Change in Short Form (36) Health Survey (SF-36)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "description": "The MFI is a patient self-reported outcome measure (questionnaires) to assess fatigue.", 
                "measure": "Change in Multidimensional Fatigue Inventory (MFI)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "description": "The visual analogue scale used is a 100 mm VAS ranging from \"no disease\" (0 mm) to \"maximal disease activity\" (100 mm).", 
                "measure": "Change in the physician's global assessment by means of Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "description": "The visual analogue scale used is a 100 mm VAS ranging from \"no disease\" (0 mm) to \"maximal disease activity\" (100 mm).", 
                "measure": "Change in the patient's global assessment by means of Visual Analog Scale (VAS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, week 12"
            }, 
            {
                "description": "The concentration of VAY736 will be measured in the serum. Descriptive statistics will include maximum serum concentration, time to reach maximum concentration, area under the concentration curve, half-life, plasma clearance.", 
                "measure": "VAY736 serum concentration", 
                "safety_issue": "No", 
                "time_frame": "0, 1, 2, 3, 6, 9, 12, 16, 20, 24 and approximately 52 weeks."
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}